Oncotarget

Lower levels of MLH1 and PMS2 are linked to temozolomide resistance and glioblastoma returning

Updated

Abstract

A reduction in expression of MLH1 and PMS2 was observed in TMZ-resistant glioblastoma cells.

  • DNA repair deficiency is related to temozolomide (TMZ) resistance in glioblastoma.
  • Three TMZ-resistant human glioblastoma cell lines were isolated for analysis.
  • Reduced levels of MLH1 were associated with decreased PMS2 protein levels in resistant cells.
  • Knockdown of MLH1 or PMS2 resulted in increased resistance to TMZ.
  • Recurrent glioblastoma tumors exhibited lower expression of MLH1 and PMS2 compared to primary tumors.

Simplified

Full Text

We can’t show the full text here under this license.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free